Teladoc Unveils Employer-Funded GLP-1 Program That Sidesteps Traditional Pharmacy Benefits
New weight care model lets companies set fixed per-fill subsidies for obesity medications while AI tracks employee engagement and clinical outcomes.

Teladoc Health has introduced a novel employer-sponsored weight management program that allows companies to directly subsidize GLP-1 medication costs outside conventional pharmacy benefit structures, marking a potential shift in how employers approach obesity treatment coverage. Announced at HLTH 2026, the program enables employers to set fixed per-fill contribution amounts while employees pay the remaining cost, creating what the company describes as a more predictable and transparent payment model.
Hybrid Payment Model Bypasses Traditional PBM Structure
The program's architecture allows employers to establish consistent payment amounts per employee per medication fill, applied uniformly across covered GLP-1 medications from manufacturers Eli Lilly and Novo Nordisk. According to Kelly Bliss, president of Teladoc Health U.S. Group Health, the model emphasizes "predictability, transparency, and access to FDA-approved authentic medications."
Teladoc manages pharmacy administration on a 100% pass-through basis, handling eligibility verification and providing audit-ready claims documentation. The company also offers consolidated invoicing and program oversight, with initial contracted clients set to launch employee programs on January 1, 2027. The offering is available immediately for employer adoption.
Employers can optionally tie their contribution levels to employee engagement metrics, including food logging frequency and regular weigh-ins, potentially creating financial incentives for program participation beyond medication access alone.
AI-Enabled Coaching and Two-Year Outcomes Data
The weight care program integrates AI-enabled food logging technology with personalized lifestyle coaching and licensed professional support, combining pharmaceutical intervention with digital health tools and behavioral modification strategies.
To support the program launch, Teladoc released research examining 22,999 members enrolled in its weight care programs over a 24-month period. The study found that 47.7% of participants achieved clinically meaningful weight loss—defined as 5% or greater reduction—by the two-year mark. Among members who lost weight in the first year, 53% continued losing additional weight during year two, suggesting sustained engagement and clinical benefit.
Implications for Employer Health Benefits
The model addresses a significant barrier to GLP-1 adoption: the high cost of medications that has strained traditional pharmacy benefit structures and led to coverage restrictions at many employers. By creating a direct payment channel that bypasses pharmacy benefit managers while maintaining clinical oversight, Teladoc offers employers budget predictability through fixed contribution amounts and potential cost containment via engagement-based incentive structures.
The integration of AI-powered tracking tools with medication access represents an emerging template for employer-direct pharmaceutical programs that combine drug interventions with digital health engagement and behavioral support. Whether this approach gains traction may depend on employer appetite for managing medication benefits outside traditional channels and the program's ability to demonstrate sustained clinical outcomes and return on investment over time.
Sources
Companies in this article
Follow Health AI Central
Keep up with health AI where you already read
On LinkedIn
The day’s strongest health AI stories in your feed, one or two each weekday.
On Google
Choose Health AI Central as a preferred source, and Google is more likely to show our reporting in Top Stories.
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.